CD48 on hematopoietic progenitors regulates stem cells and suppresses tumor formation

Blood

Volumn 118, Issue 1, 2011, Pages 80-87

  Boles, Nathan C ^a,b   Lin, Kuanyin K ^b   Lukov, Georgi L ^a   Bowman, Teresa V ^c   Baldridge, Megan T ^a   Goodell, Margaret A ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD48 ANTIGEN; CYTOKINE; P21 ACTIVATED KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CARCINOGENESIS; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 79960121483     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-322339     Document Type: Article

References (50)

1. Venezia TA, Merchant AA, Ramos CA, et al. Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol. 2004;2(10):e301.
2. Thoren LA, Liuba K, Bryder D, et al. Kit regulates maintenance of quiescent hematopoietic stem cells. J Immunol. 2008;180(4):2045-2053.
3. Chambers SM, Boles NC, Lin KY, et al. Hematopoietic fingerprints: an expression database of stem cells and their progeny. Cell Stem Cell. 2007;1(5):578-591.
4. Passegue E,Wagers AJ, Giuriato S, Anderson WC, Weissman IL. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med. 2005;202(11):1599-1611. (Pubitemid 41746605)
5. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183(4):1797-1806. (Pubitemid 26134320)
6. Wilson A, Laurenti E, Oser G, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135(6):1118-1129.
7. Baldridge M, King K, Boles N, Weksberg D, Goodell MA. Quiescent hematopoietic stem cells are activated by IFNgamma in response to chronic infection. Nature. 2010;465:793-797.
8. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121(7):1109-1121. (Pubitemid 40884400)
9. Lee KM, Forman JP, McNerney ME, et al. Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions. Blood. 2006;107(8):3181-3188.
10. Gao N, Dang T, Dunnick WA, Collins JT, Blazar BR, Yuan D. Receptors and counterreceptors involved in NK-B cell interactions. J Immunol. 2005;174(7):4113-4119. (Pubitemid 40395988)
11. Messmer B, Eissmann P, Stark S, Watzl C. CD48 stimulation by 2B4 (CD244)-expressing targets activates human NK cells. J Immunol. 2006;176(8):4646-4650.
12. Assarsson E, Kambayashi T, Persson CM, Chambers BJ, Ljunggren HG. 2B4/CD48-mediated regulation of lymphocyte activation and function. J Immunol. 2005;175(4):2045-2049. (Pubitemid 41113807)
13. Zoumbos NC, Gascon P, Djeu JY, Young NS. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A. 1985;82(1):188-192. (Pubitemid 15168240)
14. Yang L, Dybedal I, Bryder D, et al. IFN-gamma negatively modulates self-renewal of repopulating human hemopoietic stem cells. J Immunol. 2005;174(2):752-757. (Pubitemid 40094269)
15. Kawano Y, Takaue Y, Hirao A, et al. Synergistic effect of recombinant interferon-gamma and interleukin-3 on the growth of immature human hematopoietic progenitors. Blood. 1991;77(10):2118-2121.
16. Caux C, Moreau I, Saeland S, Banchereau J. Interferon-gamma enhances factor-dependent myeloid proliferation of human CD34+ hematopoietic progenitor cells. Blood. 1992;79(10):2628-2635.
17. Krutzik PO, Nolan GP. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods. 2006;3(5):361-368.
18. Mooney JM, Klem J, Wulfing C, et al. The murine NK receptor 2B4 (CD244) exhibits inhibitory function independent of signaling lymphocytic activation molecule-associated protein expression. J Immunol. 2004;173(6):3953-3961. (Pubitemid 39280759)
19. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
20. Challen GA, Boles N, Lin KK, Goodell MA. Mouse hematopoietic stem cell identification and analysis. Cytometry A. 2009;75(1):14-24.
21. Gonzalez-Cabrero J, Wise CJ, Latchman Y, Freeman GJ, Sharpe AH, Reiser H. CD48- deficient mice have a pronounced defect in CD4(+) T cell activation. Proc Natl Acad Sci U S A. 1999;96(3):1019-1023.
22. Fukushima K, Ikehara Y, Yamashita K. Functional role played by the glycosylphosphatidylinositol anchor glycan of CD48 in interleukin-18-induced interferon-gamma production. J Biol Chem. 2005;280(18):18056-18062. (Pubitemid 41389050)
23. Gonzalez-Alvaro I, Dominguez-Jimenez C, Ortiz AM, et al. Interleukin-15 and interferon-gamma participate in the cross-talk between natural killer and monocytic cells required for tumour necrosis factor production. Arthritis Res Ther. 2006;8(4):R88.
24. Carter SL, Muller M, Manders PM, Campbell IL. Induction of the genes for Cxcl9 and Cxcl10 is dependent on IFN-gamma but shows differential cellular expression in experimental autoimmune encephalomyelitis and by astrocytes and microglia in vitro. Glia. 2007;55(16):1728-1739. (Pubitemid 47612859)
25. Schatzle JD, Sheu S, Stepp SE, Mathew PA, Bennett M, Kumar V. Characterization of inhibitory and stimulatory forms of the murine natural killer cell receptor 2B4. Proc Natl Acad Sci U S A. 1999;96(7):3870-3875. (Pubitemid 29169003)
26. Stepp SE, Schatzle JD, Bennett M, Kumar V, Mathew PA. Gene structure of the murine NK cell receptor 2B4: presence of 2 alternatively spliced isoforms with distinct cytoplasmic domains. Eur J Immunol. 1999;29(8):2392-2399. (Pubitemid 29378107)
27. Riteau B, Barber DF, Long EO. Vav1 phosphorylation is induced by beta2 integrin engagement on natural killer cells upstream of actin cytoskeleton and lipid raft reorganization. J Exp Med. 2003;198(3):469-474. (Pubitemid 36976057)
28. Mainiero F, Gismondi A, Soriani A, et al. Integrin-mediated ras-extracellular regulated kinase (ERK) signaling regulates interferon gamma production in human natural killer cells. J Exp Med. 1998;188(7):1267-1275. (Pubitemid 28478015)
29. Kunstyr I, Leuenberger HG. Gerontological data of C57BL/6J mice. I. Sex differences in survival curves. J Gerontol. 1975;30(2):157-162.
30. Benoit L, Wang X, Pabst HF, Dutz J, Tan R. Defective NK cell activation in X-linked lymphoproliferative disease. J Immunol. 2000;165(7):3549-3553. (Pubitemid 32057255)
31. Bassiri H, Janice Yeo WC, Rothman J, Koretzky GA, Nichols KE. X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses. Immunol Res. 2008;42(1-3):145-159.
32. Yang W, Agrawal N, Patel J, et al. Diminished expression of CD19 in B-cell lymphomas. Cytometry B Clin Cytom. 2005;63(1):28-35. (Pubitemid 40096842)
33. Higashi M, Sugaya Y, Soeta S, Yokota A, Ishii G, Harigaya K. CD44 expression during tumor progression of follicular lymphoma. Oncol Rep. 2009;22(5):1135-1140.
34. Wu Q, Tidmarsh GF, Welch PA, Pierce JH, Weissman IL, Cooper MD. The early B lineage antigen BP-1 and the transformation-associated antigen 6C3 are on the same molecule. J Immunol. 1989;143(10):3303-3308. (Pubitemid 20010160)
35. Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev. 2009;28(1-2):51-63.
36. Heckman CA, Demuth JG, Deters D, et al. Relationship of p21-activated kinase (PAK) and filopodia to persistence and oncogenic transformation. J Cell Physiol. 2009;220(3):576-585.
37. Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R. PAK signaling in oncogenesis. Oncogene. 2009;28(28):2545-2555.
38. Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R. PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene. 2006;25(20):2931- 2936. (Pubitemid 43739243)
39. Cornish J, Gillespie MT, Callon KE, Horwood NJ, Moseley JM, Reid IR. Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. Endocrinology. 2003;144(4):1194-1201. (Pubitemid 36428459)
40. Kato K, Koyanagi M, Okada H, et al. CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation. J Exp Med. 1992;176(5):1241-1249.
41. Luckey CJ, Bhattacharya D, Goldrath AW, Weissman IL, Benoist C, Mathis D. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci U S A. 2006;103(9):3304-3309. (Pubitemid 43346465)
42. Hwang JH, Kim SW, Lee HJ, Yun HJ, Kim S, Jo DY. Interferon gamma has dual potential in inhibiting or promoting survival and growth of hematopoietic progenitors: interactions with stromal cell-derived factor 1. Int J Hematol. 2006;84(2):143-150. (Pubitemid 44343977)
43. Snoeck HW, Van Bockstaele DR, Nys G, et al. Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells. J Exp Med. 1994;180(3):1177-1182.
44. Shiohara M, Koike K, Nakahata T, Komiyama A. Hematopoietic progenitors and synergism of interferon-gamma and stem cell factor. Leuk Lymphoma. 1994;14(3-4):203-211. (Pubitemid 24241590)
45. Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904-908.
46. Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med. 2009;15(6):696-700.
47. Nichols KE, Ma CS, Cannons JL, Schwartzberg PL, Tangye SG. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev. 2005;203:180-199. (Pubitemid 40179702)
48. Tangye SG, Phillips JH, Lanier LL, Nichols KE. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J Immunol. 2000;165(6):2932-2936.
49. Brandau O, Schuster V, Weiss M, et al. Epstein-Barr virus-negative boys with nonHodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet. 1999;8(13):2407-2413.
50. Kaga S, Ragg S, Rogers KA, Ochi A. Activation of p21-CDC42/Rac-activated kinases by CD28 signaling: p21-activated kinase (PAK) and MEK kinase 1 (MEKK1) may mediate the interplay between CD3 and CD28 signals. J Immunol. 1998;160(9):4182-4189. (Pubitemid 28217271)